The race for the vaccine against the Covid-19 is accelerating, Moderna announces 94.5% of efficiency for its

The Moderna laboratory announces 94.5% effectiveness for its anti-Covid-19 vaccine.

AP Photo / Kirsty Wigglesworth, File

Text by: RFI Follow

2 min

Clinical trials of candidate vaccines against Covid-19 are progressing and the first results are starting to be made public.

After Pfizer and its 90% efficiency last week, here is Moderna announcing 94.5% efficiency for its vaccine.

Publicity

Read more

94.5% efficiency for the vaccine from the Moderna laboratory, it is the same order of magnitude as for

The two vaccine candidates share the same technology.

They are based on viral RNA, a technique still unheard of for a human vaccine, but whose preliminary research was promising.

But as for the announcement of Pfizer last week, we must put Moderna's announcement on Monday, November 16, into perspective.

This is indeed a press release that has been used: the scientific data from this clinical trial is not yet public although a little more information has been shared this time.

In particular the results concerning the elderly and or at risk.

It should also be remembered that these data are only preliminary and that it is quite likely that this announced efficacy will decrease as the clinical trial is analyzed.

That said, of course, it will have to be confirmed, but this announcement is good news especially since Moderna's vaccine candidate avoids a pitfall encountered by that of Pfizer.

No need to store it at minus 70 degrees, a refrigerator is enough for a month.

This will greatly simplify its distribution.

Newsletter

Receive all the international news directly in your mailbox

I subscribe

Follow all the international news by downloading the RFI application

google-play-badge_FR

• Coronavirus

• Health and medicine